引言：ESCRT是一个参与多种重要生理过程的分子机器，如多泡体形成、细胞自噬和细胞膜修复。CHMP7是ESCRT-III的调节亚基，对ESCRT的正常功能至关重要。本研究利用公共数据库探究了CHMP7在肿瘤中的作用。 方法：关于CHMP7在肿瘤学领域的研究相对有限。本研究通过公共数据库和临床收集的结直肠癌组织样本，分析了多种肿瘤组织中CHMP7的差异表达。随后，解析了CHMP7的突变景观、甲基化水平以及其表达水平与基因组不稳定性之间的关系。免疫微环境是肿瘤研究中一个引人注目的新兴研究领域。通过在线数据集和单细胞测序，分析了CHMP7与肿瘤微环境中各种浸润免疫细胞类型的相关性。在临床治疗方面，评估了CHMP7表达水平对化疗和免疫治疗的影响，以及与CHMP7相关的小分子药物的评价。 结果：CHMP7对肿瘤患者的预后具有预测价值，并且在肿瘤免疫中起到了重要作用。CHMP7的降低可能导致基因组不稳定性。观察到CHMP7与TME免疫细胞浸润之间存在强烈的相关性，参与了抑制性TME的形成并促进肿瘤进展。多种化疗药物的非应答组中CHMP7的表达水平显著较低。CHMP7有潜在作为预测肿瘤化疗和免疫治疗效果的新生物标志物。 结论：作为一个感兴趣的基因，CHMP7有望为进一步治疗肿瘤患者提供新的和有前景的靶点。 版权所有 © 2023 Guo, Wang, Liang和Wang。

Introduction: ESCRT is a molecular machine involved in various important physiological processes, such as the formation of multivesicular bodies, cellular autophagy, and cellular membrane repair. CHMP7 is a regulatory subunit of ESCRT-III and is necessary for the proper functioning of ESCRT. In this study, public databases were exploited to explore the role of CHMP7 in tumors. Methods: The research on CHMP7 in oncology is rather limited. In this study, the differential expression of CHMP7 in multiple tumor tissues was analyzed with information from public databases and clinically collected colorectal cancer tissue samples. Subsequently, the mutational landscape of CHMP7, methylation levels, and the relationship between its expression levels and genomic instability were resolved. The immune microenvironment is a compelling emerging star in tumor research. The correlation of CHMP7 with various infiltrating immune cell types in TME was analyzed by online datasets and single-cell sequencing. In terms of clinical treatment, the impact of CHMP7 expression levels on chemotherapy and immunotherapy and the evaluation of small molecule drugs related to CHMP7 were assessed. Results: CHMP7 has a predictive value for the prognosis of patients with tumors and is highly involved in tumor immunity. The downregulation of CHMP7 may lead to genomic instability. A strong correlation between CHMP7 and TME immune cell infiltration has been observed, participating in the formation of suppressive TME and promoting tumor progression. The expression level of CHMP7 is significantly lower in the non-responder group of multiple chemotherapeutic agents. CHMP7 can potentially serve as a new biomarker for predicting the efficacy of tumor chemotherapy and immunotherapy. Conclusion: As a gene of interest, CHMP7 is expected to provide novel and promising targets for further treatment of patients with tumor.Copyright © 2023 Guo, Wang, Liang and Wang.